Abstract
Protein-protein interactions sequester enzymes close to their substrates. Protein kinase C (PKC) is one example of a ubiquitous signaling molecule with effects that are dependent upon localization. Short peptides derived from interaction sites between each PKC isozyme and its receptor for activated C kinase act as highly specific inhibitors and have become available as selective drugs in basic research and animal models of human diseases, such as myocardial infarction and hyperglycemia. Whereas the earlier inhibitory peptides are highly specific, we believe that peptides targeting additional interactions between PKC and selective substrates will generate even more selective tools that regulate different functions of individual isozymes. Here, we discuss the methodologies and applications for identifying selective regulators of PKC.
Original language | English |
---|---|
Pages (from-to) | 25-33 |
Number of pages | 9 |
Journal | Trends in Endocrinology and Metabolism |
Volume | 20 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2009 |
Externally published | Yes |
Bibliographical note
Funding Information:D.M.-R. is the founder of KAI Pharmaceuticals, a company that plans to bring PKC regulators to the clinic. However, none of the work in her lab is supported by the company.
Funding
D.M.-R. is the founder of KAI Pharmaceuticals, a company that plans to bring PKC regulators to the clinic. However, none of the work in her lab is supported by the company.
Funders | Funder number |
---|---|
National Institutes of Health | HL76670, HL52141 |
National Institute on Alcohol Abuse and Alcoholism | R01AA011147 |